Catalysts · MRK · CIK 310158 · page 2 of 4

MRK catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on MRK PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
Oct 2027 to Jan 2028Quarter disclosedMK-8690MRKTopline readoutRheumatoid ArthritisScheduledClinicalTrials.gov
October 2027Month disclosedMK-7262MRKPrimary completionLipoprotein(a)ScheduledClinicalTrials.gov
October 2027Month disclosedMK-8527MRKPrimary completionHuman Immunodeficiency Virus (HIV); HIV Pre-Exposure ProphylaxisScheduledClinicalTrials.gov
October 2027Month disclosedMK-8690MRKPrimary completionRheumatoid ArthritisScheduledClinicalTrials.gov
October 2027Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionSmall Cell Lung CancerScheduledClinicalTrials.gov
October 2027Month disclosedMK-8690MRKPrimary completionColitis Ulcerative; Ulcerative ColitisScheduledClinicalTrials.gov
Nov 2027 to Feb 2028Quarter disclosedopevesostat (MK-5684)MRKTopline readoutMalignant NeoplasmScheduledClinicalTrials.gov
Nov 2027 to Feb 2028Quarter disclosedLipfendra (enlicitide decanoate)MRKTopline readoutHyperlipidemia; HypercholesterolemiaScheduledClinicalTrials.gov
November 2027Month disclosedopevesostat (MK-5684)MRKPrimary completionMalignant NeoplasmScheduledClinicalTrials.gov
November 2027Month disclosedLipfendra (enlicitide decanoate)MRKPrimary completionHyperlipidemia; HypercholesterolemiaScheduledClinicalTrials.gov
Dec 2027 to Mar 2028Quarter disclosedzilovertamab vedotin (MK-2140)MRKTopline readoutLymphoma, Large B-Cell, DiffuseScheduledClinicalTrials.gov
Dec 2027 to Mar 2028Quarter disclosedV503MRKTopline readoutPapillomavirus InfectionsScheduledClinicalTrials.gov
Dec 2027 to Mar 2028Quarter disclosedalimatravir (MK-8527)MRKTopline readoutHIVScheduledClinicalTrials.gov
December 2027Month disclosedalimatravir (MK-8527)MRKPrimary completionHIVScheduledClinicalTrials.gov
December 2027Month disclosedzilovertamab vedotin (MK-2140)MRKPrimary completionLymphoma, Large B-Cell, DiffuseScheduledClinicalTrials.gov
December 2027Month disclosedV503MRKPrimary completionPapillomavirus InfectionsScheduledClinicalTrials.gov
Jan to Apr 2028Quarter disclosedsacituzumab tirumotecan (MK-2870)MRKTopline readoutEndometrial CancerScheduledClinicalTrials.gov
Jan to Apr 2028Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutNon-small Cell Lung Cancer (NSCLC)ScheduledClinicalTrials.gov
Jan to Apr 2028Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutRenal Cell CarcinomaScheduledClinicalTrials.gov
Jan to Apr 2028Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutNon-small Cell Lung CancerScheduledClinicalTrials.gov
January 2028Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionRenal Cell CarcinomaScheduledClinicalTrials.gov
January 2028Month disclosedsacituzumab tirumotecan (MK-2870)MRKPrimary completionEndometrial CancerScheduledClinicalTrials.gov
January 2028Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionNon-small Cell Lung CancerScheduledClinicalTrials.gov
January 2028Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionNon-small Cell Lung Cancer (NSCLC)ScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedV503MRKTopline readoutPapillomavirus InfectionsScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedpembrolizumab (+) berahyaluronidase alfa (MK-3475A)MRKTopline readoutSquamous Cell CarcinomaScheduledClinicalTrials.gov
March 2028Month disclosedV503MRKPrimary completionPapillomavirus InfectionsScheduledClinicalTrials.gov
March 2028Month disclosedpembrolizumab (+) berahyaluronidase alfa (MK-3475A)MRKPrimary completionSquamous Cell CarcinomaScheduledClinicalTrials.gov
May to Aug 2028Quarter disclosedopevesostat (MK-5684)MRKTopline readoutMetastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic NeoplasmsScheduledClinicalTrials.gov
May 2028Month disclosedopevesostat (MK-5684)MRKPrimary completionMetastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic NeoplasmsScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedsacituzumab tirumotecan (MK-2870)MRKTopline readoutCervical CancerScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedifinatamab deruxtecan (MK-2400)MRKTopline readoutProstate Cancer; Prostatic NeoplasmsScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedWINREVAIR (sotatercept)MRKTopline readoutPulmonary Arterial HypertensionScheduledClinicalTrials.gov
June 2028Month disclosedsacituzumab tirumotecan (MK-2870)MRKPrimary completionCervical CancerScheduledClinicalTrials.gov
June 2028Month disclosedWINREVAIR (sotatercept)MRKPrimary completionPulmonary Arterial HypertensionScheduledClinicalTrials.gov
June 2028Month disclosedifinatamab deruxtecan (MK-2400)MRKPrimary completionProstate Cancer; Prostatic NeoplasmsScheduledClinicalTrials.gov
Jul to Oct 2028Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutHigh-risk Non-muscle Invasive Bladder CancerScheduledClinicalTrials.gov
Jul to Oct 2028Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutMalignant MelanomaScheduledClinicalTrials.gov
July 2028Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionMalignant MelanomaScheduledClinicalTrials.gov
July 2028Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionHigh-risk Non-muscle Invasive Bladder CancerScheduledClinicalTrials.gov
Aug to Nov 2028Quarter disclosedsacituzumab tirumotecan (MK-2870)MRKTopline readoutNon-small Cell Lung Cancer (NSCLC)ScheduledClinicalTrials.gov
August 2028Month disclosedsacituzumab tirumotecan (MK-2870)MRKPrimary completionNon-small Cell Lung Cancer (NSCLC)ScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutColorectal NeoplasmsScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedWINREVAIR (sotatercept)MRKTopline readoutPulmonary Arterial HypertensionScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutMalignant Neoplam; Advanced Solid TumorsScheduledClinicalTrials.gov
September 2028Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionColorectal NeoplasmsScheduledClinicalTrials.gov
September 2028Month disclosedWINREVAIR (sotatercept)MRKPrimary completionPulmonary Arterial HypertensionScheduledClinicalTrials.gov
September 2028Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionMalignant Neoplam; Advanced Solid TumorsScheduledClinicalTrials.gov
Oct 2028 to Jan 2029Quarter disclosediv tulisokibart (PRA023)MRKTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Oct 2028 to Jan 2029Quarter disclosedLipfendra (enlicitide decanoate)MRKTopline readoutHypercholesterolemiaScheduledClinicalTrials.gov
Oct 2028 to Jan 2029Quarter disclosedtiespectus (MK-8748)MRKTopline readoutDiabetic Retinopathy; Macular EdemaScheduledClinicalTrials.gov
October 2028Month disclosedLipfendra (enlicitide decanoate)MRKPrimary completionHypercholesterolemiaScheduledClinicalTrials.gov
October 2028Month disclosediv tulisokibart (PRA023)MRKPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
October 2028Month disclosedtiespectus (MK-8748)MRKPrimary completionDiabetic Retinopathy; Macular EdemaScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedPifeltro (doravirine)MRKTopline readoutHuman Immunodeficiency Virus (HIV) InfectionScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedopevesostat (MK-5684)MRKTopline readoutProstate Cancer MetastaticScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedpembrolizumab (+) berahyaluronidase alfa (MK-3475A)MRKTopline readout—ScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedtiespectus (MK-8748)MRKTopline readoutDiabetic Retinopathy; Macular EdemaScheduledClinicalTrials.gov
November 2028Month disclosedpembrolizumab (+) berahyaluronidase alfa (MK-3475A)MRKPrimary completion—ScheduledClinicalTrials.gov
November 2028Month disclosedPifeltro (doravirine)MRKPrimary completionHuman Immunodeficiency Virus (HIV) InfectionScheduledClinicalTrials.gov
November 2028Month disclosedopevesostat (MK-5684)MRKPrimary completionProstate Cancer MetastaticScheduledClinicalTrials.gov
November 2028Month disclosedtiespectus (MK-8748)MRKPrimary completionDiabetic Retinopathy; Macular EdemaScheduledClinicalTrials.gov
Dec 2028 to Mar 2029Quarter disclosedWINREVAIR (sotatercept)MRKTopline readoutPulmonary Arterial HypertensionScheduledClinicalTrials.gov
December 2028Month disclosedWINREVAIR (sotatercept)MRKPrimary completionPulmonary Arterial HypertensionScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosednemtabrutinib (ARQ-531)MRKTopline readoutHematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins LymphomaScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutNon-small Cell Lung Cancer; NSCLCScheduledClinicalTrials.gov
January 2029Month disclosednemtabrutinib (ARQ-531)MRKPrimary completionHematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins LymphomaScheduledClinicalTrials.gov
January 2029Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionNon-small Cell Lung Cancer; NSCLCScheduledClinicalTrials.gov
Feb to May 2029Quarter disclosed9vhpv vaccine (V503)MRKTopline readoutGenital WartsScheduledClinicalTrials.gov
February 2029Month disclosedisl (MK-8591)MRKPrimary completionHuman Immunodeficiency Virus Type 1 (HIV-1) InfectionScheduledClinicalTrials.gov
Feb to May 2029Quarter disclosedisl (MK-8591)MRKTopline readoutHuman Immunodeficiency Virus Type 1 (HIV-1) InfectionScheduledClinicalTrials.gov
February 2029Month disclosed9vhpv vaccine (V503)MRKPrimary completionGenital WartsScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedcalderasib (MK-1084)MRKTopline readoutColon Adenocarcinoma; Rectal AdenocarcinomaScheduledClinicalTrials.gov
March 2029Month disclosedcalderasib (MK-1084)MRKPrimary completionColon Adenocarcinoma; Rectal AdenocarcinomaScheduledClinicalTrials.gov
Apr to Jul 2029Quarter disclosedzilovertamab vedotin (MK-2140)MRKTopline readoutLymphoma, Large B-Cell, Diffuse (DLBCL)ScheduledClinicalTrials.gov
Apr to Jul 2029Quarter disclosedsacituzumab tirumotecan (MK-2870)MRKTopline readoutOvarian Cancer; Fallopian Tube Cancer; Primary Peritoneal CancerScheduledClinicalTrials.gov
Apr to Jul 2029Quarter disclosedMK-2214MRKTopline readoutEarly Alzheimer's DiseaseScheduledClinicalTrials.gov
Apr to Jul 2029Quarter disclosedOhtuvayre (ensifentrine)MRKTopline readoutPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
April 2029Month disclosedzilovertamab vedotin (MK-2140)MRKPrimary completionLymphoma, Large B-Cell, Diffuse (DLBCL)ScheduledClinicalTrials.gov
April 2029Month disclosedsacituzumab tirumotecan (MK-2870)MRKPrimary completionOvarian Cancer; Fallopian Tube Cancer; Primary Peritoneal CancerScheduledClinicalTrials.gov
April 2029Month disclosedOhtuvayre (ensifentrine)MRKPrimary completionPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
April 2029Month disclosedMK-2214MRKPrimary completionEarly Alzheimer's DiseaseScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedMK-8591AMRKTopline readoutHIV-1 InfectionScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosed9vhpv vaccine (V503)MRKTopline readoutPapillomavirus InfectionsScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedzilovertamab vedotin (MK-2140)MRKTopline readoutChronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular LymphomaScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedWINREVAIR (sotatercept)MRKTopline readoutPulmonary Arterial HypertensionScheduledClinicalTrials.gov
May 2029Month disclosedzilovertamab vedotin (MK-2140)MRKPrimary completionChronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular LymphomaScheduledClinicalTrials.gov
May 2029Month disclosedWINREVAIR (sotatercept)MRKPrimary completionPulmonary Arterial HypertensionScheduledClinicalTrials.gov
May 2029Month disclosed9vhpv vaccine (V503)MRKPrimary completionPapillomavirus InfectionsScheduledClinicalTrials.gov
May 2029Month disclosedMK-8591AMRKPrimary completionHIV-1 InfectionScheduledClinicalTrials.gov
Jun to Sep 2029Quarter disclosedtulisokibart (PRA023)MRKTopline readoutNoninfectious Intermediate, Posterior, or PanuveitisScheduledClinicalTrials.gov
June 2029Month disclosedtulisokibart (PRA023)MRKPrimary completionNoninfectious Intermediate, Posterior, or PanuveitisScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedzilovertamab vedotin (MK-2140)MRKTopline readoutDiffuse Large B-Cell LymphomaScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedKEYTRUDA® (pembrolizumab)MRKTopline readoutSquamous Non-small Cell Lung CancerScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedsacituzumab tirumotecan (MK-2870)MRKTopline readoutBladder CancerScheduledClinicalTrials.gov
July 2029Month disclosedzilovertamab vedotin (MK-2140)MRKPrimary completionDiffuse Large B-Cell LymphomaScheduledClinicalTrials.gov
July 2029Month disclosedKEYTRUDA® (pembrolizumab)MRKPrimary completionSquamous Non-small Cell Lung CancerScheduledClinicalTrials.gov
July 2029Month disclosedsacituzumab tirumotecan (MK-2870)MRKPrimary completionBladder CancerScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosed9vhpv vaccine (V503)MRKTopline readoutPapillomavirus InfectionsScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedVerquvo (vericiguat)MRKTopline readoutHeart Failure; Left Ventricular Systolic DysfunctionScheduledClinicalTrials.gov
Every catalyst is quoted from MRK’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.